APHARMAS -

Description:

This service is based on advantage of lentiviral vectors that can stably deliver shRNA into primary cells or cell lines with up to 100% efficiency. Our Lenti-Ready^sm Technology provides higher efficiency and more flexibility to meet customers' needs. Ready-to-use deliverables are suitable for in vitro and/or in vivo applications.

If commercial shRNAs of your target gene are not available or non-functional, or your project requires special design and/or IP-protection for further development, we meet your needs!

• One-stop service: from shRNA desigh to packaging
• Quick turnaround time: 4 to 6 weeks
• Cost-effective
• Special design request and custom protocol acceptable

Requirements & Deliverables:

Only GenBank accession number or a DNA sequence is needed.

We deliver:

√ Viral supernatants
√ Infection reference protocol

Options:

* Choice of selection marker: Blasticidin or GFP or your marker;
* Constitutive or inducible;
* Concentration for in vivo application;
* Packaging-only if you already have a construct;
* Re-order of additional volume at reduced cost.

Service Documents (Registered User ONLY):

• General service information (Login)

Reference:

1. Terashima, A, etc. An Essential Role for PICK1 in NMDA Receptor-Dependent Bidirectional Synaptic Plasticity. Neuron. 2008 March 27; 57(6): 872-882.
2. Harwood, FC, etc. mTORC1 Signaling Can Regulate Growth Factor Activation of p44/42 Mitogen-activated Protein Kinases through Protein Phosphatase 2A. J. Biol. Chem. 283, 2575-2585.
3. Sha et al. A Critical Role for CHIP in the Aggresome Pathway.Molecular and Cellular Biology, January 2009, p. 116-128, Vol. 29, No. 1
4. Monroe et al.  Retinoblastoma binding protein-1(RBP1) is a Runx2 coactivator and promotes osteoblastic differentiation. BMC Musculoskeletal Disorders 2010, 11:104

For more technical details and cost information, please This e-mail address is being protected from spambots. You need JavaScript enabled to view it .